PH4 Stock Overview
CStone Pharmaceuticals, a biopharmaceutical company, researches, develops, and commercializes immuno-oncology and precision medicines to address the unmet medical needs of cancer patients in China and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
CStone Pharmaceuticals Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$0.14 |
| 52 Week High | HK$0.36 |
| 52 Week Low | HK$0.092 |
| Beta | 0.16 |
| 1 Month Change | 32.04% |
| 3 Month Change | -25.03% |
| 1 Year Change | -61.69% |
| 3 Year Change | -86.40% |
| 5 Year Change | n/a |
| Change since IPO | -90.46% |
Recent News & Updates
Recent updates
Shareholder Returns
| PH4 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 9.7% | -0.7% | 2.5% |
| 1Y | -61.7% | -21.2% | 5.4% |
Return vs Industry: PH4 underperformed the German Biotechs industry which returned -23.6% over the past year.
Return vs Market: PH4 underperformed the German Market which returned 4.6% over the past year.
Price Volatility
| PH4 volatility | |
|---|---|
| PH4 Average Weekly Movement | 15.5% |
| Biotechs Industry Average Movement | 5.3% |
| Market Average Movement | 5.0% |
| 10% most volatile stocks in DE Market | 10.5% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: PH4's share price has been volatile over the past 3 months.
Volatility Over Time: PH4's weekly volatility (16%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | 474 | Jason Yang | www.cstonepharma.com |
CStone Pharmaceuticals, a biopharmaceutical company, researches, develops, and commercializes immuno-oncology and precision medicines to address the unmet medical needs of cancer patients in China and internationally. It offers Sugemalimab, a monoclonal antibody against programmed death (PD) ligand 1; GAVRETO, an RET inhibitor for the treatment of patients with advanced or metastatic RET-mutant medullary and RET fusion-positive thyroid cancers; and avapritinib, a KIT/PDGFRA inhibitor to treat adults with unresectable or metastatic gastrointestinal stromal tumors harboring a PDGFRA exon 18 mutation. The company’s product pipeline includes Nofazinlimab, a PD-1 antibody for the treatment of patients with hepatocellular carcinoma; and Ivosidenib, an isocitrate dehydrogenase 1 (IDH1) inhibitor to treat adults with relapsed or refractory acute myeloid leukemia with an IDH1 mutation.
CStone Pharmaceuticals Fundamentals Summary
| PH4 fundamental statistics | |
|---|---|
| Market cap | €175.58m |
| Earnings (TTM) | -€47.17m |
| Revenue (TTM) | €59.58m |
2.9x
P/S Ratio-3.7x
P/E RatioIs PH4 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PH4 income statement (TTM) | |
|---|---|
| Revenue | CN¥463.84m |
| Cost of Revenue | CN¥159.55m |
| Gross Profit | CN¥304.30m |
| Other Expenses | CN¥671.53m |
| Earnings | -CN¥367.23m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.29 |
| Gross Margin | 65.60% |
| Net Profit Margin | -79.17% |
| Debt/Equity Ratio | 69.8% |
How did PH4 perform over the long term?
See historical performance and comparison